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Conclusion: Radical radiotherapy is feasible and effective for 
elderly or unfit patients. Three-year locoregional control 
after radical radiotherapy using a boost technique was 72%, 
with low rates for late urinary and intestinal toxicity. Early 
and late toxicity rates were reduced by using IMRT. 
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Purpose or Objective: We conducted a phase I trial of 
Gemcitabine (GEM) with concomitant 3D-Conformal 
Radiotherapy (3D-CRT) and Cisplatin (CDDP) in patients with 
muscle-invasive bladder cancer who were ineligible for 
surgery or refused organ loss. 
 
Material and Methods: 28 patients with transitional cell 
carcinoma, cT2(n=14), cT3(n=8), T4a(n=6), cN0-1, M0, 
median age 70.5 years were included after maximal 
transurethral resection. 3D-CRT was administered with a 
18MV Linac, 1.8Gy/Fr, 5d/week up to 64.80Gy. The GEM 
starting dose of 40mg/m2/week was increased by 40mg/m2 
increments to 2 levels (80 and 120mg/m2/week) in cohorts of 
6 patients. The standard dose of CDDP was 25mg/m2/week 
given 2 days after GEM infusion. Both drugs were given 30 to 
60min before irradiation 
 
Results: All patients were evaluated for toxicity which was 
evaluated according to the Common Toxicity Criteria and the 
RTOG/EORTC Score. The DLTs (Dose Limiring Toxicities) were 
defined as hematologic grade >3 or Non-hematologic grade 3 
events, as Abdominal pain/Diarrhea (Proctitis), 
Dysuria/Urinary frequency (Cystitis), Fatigue/Asthenia, not 
resolving tro grade 1/2 within 2 days or necessitating the 
interruption of RT for >1 week, in more than 3 of 6 patients 
in each cohort. The GEM dose immediately before the level 
at which the DLT was observed was defined as the Maximum 
Tolerated Dose (MTD). In 6 patients accrued to GEM dose 
40mg/m2/week no grade 3 toxicities were seen. From 6 
patients given 80mg/m2/week of GEM, 2 had episodes of 
grade 3 bladder toxicity, 3 General Weakness and 2 
presented with grade 3 hematological sequelae. From 6 
patients accrued to GEM dose 120mg/m2/week, 4 had 
episodes of grade 3 neutropenia and/or thrombocytopenia 
and 3 showed grade 3 fatigue/malaise. In 4 patients 
treatment was interrupted for more than 1 week. The 2-year 
locoregional failure rate was 28% (8/28). 12 of 28 (42%) 
patients are alive with no evidence of disease progression, 8 
patients developed M1 disease and 5 died from this. 
 
Conclusion: GEM given synchronously with 3D-CRT is well 
tolerated as a bladder preservation schema. The MTD was 
defined at 80mg/m2/week combined to CDDP and merits 
evaluation in phase II/III trials. 
 
Poster: Clinical track: Skin cancer / malignant melanoma  
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Purpose or Objective: Wide surgical excision is the standard 
treatment for angiosarcoma of the scalp, but it is often 
difficult to completely excise because of the invasive nature 
and typical multifocal spread of the tumor. Furthermore, 
many patients are medically inoperable because of old age or 
coexisting disease. Therefore, we investigated the outcome 
of radiation therapy with total scalp irradiation for 
angiosarcoma of the scalp. 
 
Material and Methods: Seventeen patients with 
angiosarcoma of the scalp underwent radiation therapy with 
total scalp irradiation with curative intent. Their median age 
at the time of irradiation was 77 (range, 57–89) years. Four of 
the 17 patients had tumor invasion into the deep organs, 
including the skull in three and the temporal muscle in one. 
Four patients had cervical lymph node metastases, but none 
had distant metastases. A median initial dose of 50 Gy in 25 
fractions was delivered to the entire scalp. Two pairs of 
lateral X-ray and electron fields were used for total scalp 
irradiation: 4–6 MV X-rays were delivered through bilaterally 
opposed ports to the central scalp from the frontal eminence 
to the suboccipital region, to a depth of 10 mm inside the 
skull, and 5–9 MeV electrons were delivered through single 
ports to the bilateral temporal scalp. Subsequently, local 
radiation boost to the tumor sites achieved a median total 
dose of 70 Gy in 35 fractions. 
Results: All irradiated tumors disappeared or were markedly 
reduced after radiation therapy; the objective response rate 
was 100%. However, 14 of the 17 patients developed 
recurrences during the median follow-up period of 14 months 
after radiation therapy; seven had recurrences in the scalp, 
including primary tumor progression in two patients and new 
disease in five, and 12 patients developed distant 
metastases. The two patients with primary tumor progression 
originally had tumor invasion into the skull and temporal 
muscle, and received a total radiation dose of 70 Gy in 35 
fractions. The primary progression-free, scalp relapse-free, 
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and distant metastasis-free rates were 86%, 67%, and 38% at 
1 year and 86%, 38%, and 16% at 3 years, respectively. 
Thirteen patients died; the cause of death was tumor 
progression in 10 patients, infectious pneumonia in two, and 
old age in one. The overall and cause-specific survival rates 
were both 73% at 1 year and 23% and 44% at 3 years, 
respectively. The median survival time was 16 months. 
Although all 17 patients developed grade 1–2 radiation 
dermatitis, there were no therapy-related toxicities of grade 
≥3. 
 
Conclusion: Total scalp irradiation with X-rays and electrons 
is safe and effective for local tumor control of angiosarcoma 
of the scalp, but a prophylactic dose of ≤50 Gy in 
conventional fractions may be insufficient to eradicate 
microscopic disease. For gross tumors, a total dose of 70 Gy, 
and >70 Gy for tumors with deep invasion, is recommended. 
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Purpose or Objective: Uveal melanoma (UM) is a life 
threatening intraocular malignant tumor in adults. Gamma 
Knife Stereotactic Radiosurgery (GKSRS) is a well assessed 
strategy for conservative treatment of UM providing 
satisfactory results in terms of survival, local control and eye 
preservation. Despite severe side effects following GKSRS 
have been reported, literature studies designed to 
investigate dose effect relationship of critical structures are 
rather poor. The aim of this work is to develop predictive 
models for radio induced effects in UM patients (pts) treated 
with GKSRS. 
 
Material and Methods: In our institute 149 pts were treated 
with exclusive GKSRS for UM between 1994 and 2014. 
Prospectively collected clinical data are available. For 
66/149 pts, 3D dosimetry data of involved critical structures 
could be recovered: optic nerve (ON), eyeball and posterior 
part of bulb. For this cohort of pts the median follow up of 
2years (6 months-6 years) is available. Cox’s analyses were 
used to identify selected clinical and dosimetric variables as 
independent risk factor of main side effects: cataract, 
radiation vasculopathy (RV), radiation papillopathy (RP) and 
neovascular glaucoma (NVG), visual acuity (VA) reduction > 
20% of basal value (VA20%) and complete loss of basal VA 
(VA100%). ROC curve analysis allowed predicting cut off value 
of significant variables. 
 
Results: The 2 years incidences from our data were: cataract 
39%, RV 10%, RP 12%, NVG 14%, VA20% 59% and VA100% 27%. 
Age and sex did not result significant. Concerning cataract 
the volume of whole bulb receiving more than 30Gy 
(p=0.0004) and tumor thickness (p=0.002) resulted highly 
predictive; best cut off were respectively 82.2mm3 and 
6.6mm. A clear relationship with maximum dose (Dmax) to 
ON was found for RP (p=0.009 cut off: 14.9Gy) and RV 
(p=0.0009 cut off: 23.8Gy). For RV, also tumor in the anterior 
to equator position was predictive (p=0.008). The volume of 
the posterior bulb receiving more than 20Gy (p=0.0003, cut 
off: 413.7mm3) and tumor thickness (p=0.0009 cut off: 
8.7mm) were predictive for NVG. Multivariate analyses 
resulted in two variables predictive model both for VA20% 
(AUC=0.79) and for VA100% (AUC=0.83), including the tumor 
longest basal diameter and Dmax to the ON. The best cut off 
values for the tumor longest basal diameter were 11.6mm for 
VA20% (p=0.02) and 8.98mm for VA100% (p=0.007); the best 
cut off values for Dmax to the ON were 7.8Gy (p=0.045) for 
VA20% and 13.2Gy (p=0.002) for VA100%. A summary of the 
main results are reported in Figure. 
 
 
 
 
Conclusion: We found clinical and dosimetric variables to 
clearly predict the risk of the main side effects after GKSRS 
for UM. These results may provide new dose constraints to 
critical structures, that once implemented during treatment 
planning, could reduce radiation toxicities. Further 
investigation to create bulb dose surface maps highlighting 
any specific regions more radiosensitive are now under 
implementation. 
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Purpose or Objective: Choroidal melanoma is the most 
frequent malignant tumour of the eye. Eye-conserving 
treatment with Ruthenium-106 brachytherapy (RuBT) is a 
standard treatment for patients with small to intermediate 
size melanomas. The present study was done to evaluate 
